HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) but reduced the price target from $58 to $52.
November 20, 2023 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
SpringWorks Therapeutics' Buy rating is maintained by HC Wainwright & Co., but the price target is lowered from $58 to $52.
While the Buy rating reaffirmation is positive, the reduction in price target could signal a tempered but still optimistic outlook on the company's valuation, which may have a neutral short-term impact on the stock price as these two factors could balance each other out.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100